Clinical trial
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)
NCT04960579 is registered in ClinicalTrials.gov with Poseida Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)
- Lead sponsor
- Poseida Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- May 5, 2022
- Completion date
- March 31, 2042
- Enrollment
- 275 (estimated)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.